JPS59107264A - Measuring method of total bilirubin in blood - Google Patents

Measuring method of total bilirubin in blood

Info

Publication number
JPS59107264A
JPS59107264A JP21763782A JP21763782A JPS59107264A JP S59107264 A JPS59107264 A JP S59107264A JP 21763782 A JP21763782 A JP 21763782A JP 21763782 A JP21763782 A JP 21763782A JP S59107264 A JPS59107264 A JP S59107264A
Authority
JP
Japan
Prior art keywords
acid
bilirubin
reaction
results
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP21763782A
Other languages
Japanese (ja)
Inventor
Toshihito Kanejima
才仁 金島
Toshihiro Yano
谷野 智弘
Yoshie Koyama
小山 美絵
Masanari Akatsuka
赤塚 真成
Hitoshi Nakajima
仁 中島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanko Junyaku Co Ltd
Original Assignee
Sanko Junyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanko Junyaku Co Ltd filed Critical Sanko Junyaku Co Ltd
Priority to JP21763782A priority Critical patent/JPS59107264A/en
Publication of JPS59107264A publication Critical patent/JPS59107264A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/728Bilirubin; including biliverdin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

PURPOSE:To enable exact measurement in a measuring method of total bilirubin using a stabilized diazonium salt by using diphiline as a reaction accelerator and using an org. acid for a buffer system. CONSTITUTION:A stabilized diazomium salt which is heretofore used is usable and the amt. of the diphiline to be used as a reaction accelerator is preferably 2-10g/dl, more preferably 4g/dl. The larger amt. results in much blank reaction and the smaller amt. in retarded acceleration of reaction. A preferred org. acid has strong buffer power at around 3pH and the acid having about 2-5pKa is preferable. Citric acid, succinic acid, maleic acid, tartaric acid, acetic acid and their salt and other org. acid are used. The pH of the buffer system is preferably 2-4, and around 3pH is best preferred. Excessively high pH results in poor stability and excessively low pH results in poor reactivity.

Description

【発明の詳細な説明】 本発明は、血液中の総ビリルビンの正確かつ効率的な測
定方法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an accurate and efficient method for measuring total bilirubin in blood.

ビリルビンは、網状内で老廃赤血球がこわれて生成する
ものと、一部ではあるが骨髄を経ないで直接ヘムタンパ
クから生成するものとがあ葛。生体中のどリルビンは、
間接型ビリルビンと直接型ビリルビンとに分類される。
Bilirubin is produced by the destruction of old red blood cells within the reticulum, and some bilirubin is produced directly from heme proteins without going through the bone marrow. Throat rirubin in the living body is
It is classified into indirect bilirubin and direct bilirubin.

間接型ビリルビンはビリルビンそのものであり、水に極
めて難溶性であるが、血液中でアルブミンと結合して水
溶化されている。一方、直接型ビリルビンは、抱合型ビ
リルビンともいわれるごとくビリルビンに主としてグル
クロン酸結合したもので水に溶は易い構造になっている
。直接型ビリルビンは、ジアゾ試薬と直接反応させて測
定される。そして、グイフィリン、安息香酸ナトリウム
−カフェイン、界面活性剤、エチレングリコール、ジメ
チルスルホキサイドなどの有機溶媒を促進剤として加え
て測定されるものを総ビリルビンと称している。総ビリ
ルビンは、間接型ビリルビンと直接型ビリルビンとう包
含するものである。
Indirect bilirubin is bilirubin itself, and is extremely poorly soluble in water, but is made water-soluble by binding to albumin in the blood. On the other hand, direct bilirubin, also called conjugated bilirubin, is bilirubin mainly bound to glucuronic acid, and has a structure that is easily soluble in water. Direct bilirubin is measured by direct reaction with a diazo reagent. Total bilirubin is measured by adding an organic solvent such as guiphylline, sodium benzoate-caffeine, surfactant, ethylene glycol, or dimethyl sulfoxide as an accelerator. Total bilirubin includes indirect bilirubin and direct bilirubin.

このビリルビンの測定法において、古典的なEve l
yn−Ma l l oy法、Jendrassik法
、アルカリアゾビリルビン法にかわるものとして、試薬
の安定性がよくしかも操作が簡便な安定化ジアゾニウム
塩法というものが最近使われるようになってきた。この
方法で用いられる安定化ジアゾニウム塩としては、2.
4−ジクロルフェニルナフタリンジスルホン酸塩、2,
5−ジク、ロルフェニル四フッ化ホウ酸塩などが知られ
、これらはビリルビンとの反応の発色剤として用いられ
る。
In this bilirubin measurement method, the classical Eve l
As an alternative to the yn-Malloy method, Jendrassik method, and alkaline azobilirubin method, the stabilized diazonium salt method, which has good reagent stability and is easy to operate, has recently come into use. The stabilized diazonium salts used in this method include 2.
4-dichlorophenylnaphthalene disulfonate, 2,
5-dichloride, lorphenyl tetrafluoroborate, and the like are known, and these are used as coloring agents for reaction with bilirubin.

現在市販されている各種安定化ジアゾニウム塊法試薬を
みるに、通常の検体を扱うかぎり古典的方法よりも操作
性、測定精度ともすぐれているが、人工透析の検体につ
いて界雷な高値を出すことが多く、測定できないという
欠点があった。この点が、安定化ジアゾニウム塩を用い
る際の唯一の大きな問題とされていたものであった。人
工透析検体について高値がでる要因としてGよ、腎機能
力く正常に働かないために血中番こ蓄積されるインジカ
ン及びその類似物質が関係してし)るものと考えられる
。たしかに、人工透析検体の反応性とインジ、カンの反
応性は似かよっている。ビリルビンの反応は、数分〜5
分以内に終わるのに対して、人工透析検体はインジカン
と同様緩やかな反応を示す。このことは、人工透析検体
にはインジカン様物質が含まれていることを示唆するも
のと考えられる。
Looking at the various stabilized diazonium bulk method reagents currently available on the market, they are superior in operability and measurement accuracy to classical methods when dealing with normal samples, but they produce extremely high values when used for artificial dialysis samples. There were many problems, and the drawback was that it could not be measured. This point was considered to be the only major problem when using stabilized diazonium salts. The cause of high values in artificial dialysis specimens is thought to be related to indican and its similar substances, which accumulate in the blood due to abnormal kidney function. It is true that the reactivity of artificial dialysis specimens is similar to that of indica and can. Bilirubin reaction takes several minutes to 5
The reaction is completed within minutes, whereas artificial dialysis samples show a slow reaction similar to indican. This is considered to suggest that the artificial dialysis specimen contains an indican-like substance.

本発明者は、上記のごとき安定化ジアゾニウム塩法にお
ける欠点を排除すべく鋭意研究した結果本発明に到達し
たものである。
The present inventor has arrived at the present invention as a result of intensive research aimed at eliminating the drawbacks of the stabilized diazonium salt method as described above.

本発明は、安定化ジアゾニウム塩法において、人工透析
検体の総ビリルビンをも正確に測定できるようにした測
定法を提供することを目的とする本発明の要旨は、安定
化ジアゾニウム塩を用し)る総ビリルビンの測定法にお
いて、反応促進剤としてグイフィリンを用い、緩衝系に
有機酸を用いることを特徴とする総ビリルビンの測定法
に存する。
The purpose of the present invention is to provide a measurement method that can accurately measure total bilirubin in an artificial dialysis sample using the stabilized diazonium salt method. The method for measuring total bilirubin is characterized by using guiphylline as a reaction accelerator and using an organic acid as a buffer system.

安定化ジアゾニウム塩としては、従来がら用いられるも
のが使用可能であり、例えば、特願昭57−64190
号に示された2、4−ジクロルフェニルジアゾニウム−
1,5−ナフタリンジスルホン酸及びその塩類(例えば
、ナトリウム塩、カリウム塩など)、p−スルファニル
ベンゼンジアゾニウム−1,5−ナフタリンスルホン酸
及びその塩類、バラニトロベンゼンジアゾニウム四フフ
化ホウ酸及びその塩類、ジアゾ化スルファニル酸四フフ
化ホウ酸及びその塩類などが用いられる。
As the stabilizing diazonium salt, those conventionally used can be used; for example, those disclosed in Japanese Patent Application No. 57-64190
2,4-dichlorophenyldiazonium- shown in No.
1,5-naphthalene disulfonic acid and its salts (e.g., sodium salt, potassium salt, etc.), p-sulfanylbenzenediazonium-1,5-naphthalene sulfonic acid and its salts, varanitrobenzenediazonium tetrafluoroboric acid and its salts, Diazotized sulfanilic acid, tetrafluoroboric acid, salts thereof, and the like are used.

グイフィリンの使用量は、2〜10g/Lil程度が好
ましく、約4g/luが最適である。量が多いとブラン
ク反応が多くなってしまい、量が少ないと反応の促進性
が弱くなる。
The amount of guiphylline used is preferably about 2 to 10 g/Lil, and optimally about 4 g/lu. If the amount is large, the blank reaction will increase, and if the amount is small, the promotion of the reaction will be weak.

有機酸としては、pH3付近で緩衝能力の強いものを選
べばよく、pKa値も2〜5位のものが好ましい。具体
的にはクエン酸及びその塩類、コハク酸及びその塩類、
マレイン酸及びその塩類、酒石酸及びその塩類、酢酸及
びその塩類及びその他の有機酸が用いられ、その使用濃
度は5〜2゜Ommol/#が好ましく、10mmo 
I /I1.カ最適である。
As the organic acid, one with a strong buffering capacity at around pH 3 may be selected, and one with a pKa value of 2 to 5 is preferable. Specifically, citric acid and its salts, succinic acid and its salts,
Maleic acid and its salts, tartaric acid and its salts, acetic acid and its salts, and other organic acids are used, and the concentration used is preferably 5 to 2゜Ommol/#, and 10mmol/#.
I/I1. It is optimal.

また、緩衝系のp)(は2〜4がよく、pH3゜0付近
が最も好ましい。pHが高くなると安定化ジアゾニウム
塩の安定性が悪くなり、])Hが低くなるとビリルビン
との反応性が悪くなる。
In addition, p)( of the buffer system is preferably 2 to 4, and most preferably around pH 3.0. As the pH increases, the stability of the stabilized diazonium salt deteriorates, and as the ])H decreases, the reactivity with bilirubin decreases. Deteriorate.

以下に本発明の実施例をあげる。Examples of the present invention are given below.

実施例1 試薬の調製 2.4−ジクロルフェニルジアゾニウム−1,5−ナフ
タリンジスルホン酸ナトリウム ー−−一一−−−−−−−−−−−−−−−−−・−・
−・−50呵/dIグイフィリン−画・−−−−−−・
−町−−−−−−−−−4g 、#/クエン酸−・−−
−−−−−−・−由−−−−−一−−曲曲−210■/
dIp)Iは3.0に調整した。
Example 1 Preparation of reagent 2. Sodium 4-dichlorophenyldiazonium-1,5-naphthalene disulfonate ----
-・-50 呵/dI Guifilin-Illustrated・-------・
-Machi------4g, #/citric acid---
-------・-Yu------1--Song-210■/
dIp)I was adjusted to 3.0.

測定方法 試薬3 m Itに試料0.1mj!を加え、37℃で
20分間反応させたのち、540nm〜570nmで測
定をおこなった。
Measurement method: 3 m of reagent and 0.1 mj of sample! was added and reacted at 37° C. for 20 minutes, and then measurements were performed at 540 nm to 570 nm.

測定項目 (1)ビリルビン(ビリルビン4M?J=物’R12■
/dl)とインジカン(インドキシル硫酸カリウム、半
井化学製、lomg/dりの反応後の吸収スペクトルを
測定した。結果は第1図に示した。
Measurement item (1) Bilirubin (bilirubin 4M?J = substance'R12■
/dl) and indicane (potassium indoxyl sulfate, manufactured by Hanui Chemical Co., Ltd., lomg/dl) after the reaction. The results are shown in FIG.

(2)ビリルビン量を一定(5mg/dI)とし、イン
ジカンの量を変化させて540nmで測定した。結果は
第1表に示した。
(2) The amount of bilirubin was kept constant (5 mg/dI), and the amount of indican was varied and measured at 540 nm. The results are shown in Table 1.

(3)正審検体と人工透析検体とを540nm及び57
0nmで測定した。結果は第2表に示した実施例2 実施例1のクエン酸のかわりにコハク酸118.7(U
を用いて試薬を調製し、測定項目(1)について同様の
測定を行った。結果喰第2図に示し。
(3) Test the original trial sample and the artificial dialysis sample at 540 nm and 57 nm.
Measured at 0 nm. The results are shown in Table 2. Example 2 Succinic acid 118.7 (U) was used instead of citric acid in Example 1.
A reagent was prepared using the same method, and the same measurement was performed for measurement item (1). The results are shown in Figure 2.

た。Ta.

実施例3 実施例1のクエン酸のかわりにマレイン酸98mg/d
lを用いて試薬を調製し、測定項目(1)につ比較例 試薬の調製 2.4−ジクロルフェニルジアゾニウム−1,5−ナフ
タリンジスルホン酸ナトリウム −−−〜−−−−−−−−−−−−−−−−−一−−5
0mgBrij35(花王アトラス製)−4,5g  
Example 3 Maleic acid 98 mg/d instead of citric acid in Example 1
Preparation of comparative example reagent 2. Sodium 4-dichlorophenyldiazonium-1,5-naphthalene disulfonate −−−−−−−−−1−−5
0mg Brij35 (manufactured by Kao Atlas) - 4.5g
.

0、’05NHClで全量を100rr+j!とじた。0, '05NHCl total amount 100rr+j! Closed.

上記試薬を用いて測定項目(1)’  (2)(3)に
ついて測定を行った(測定項目(3)については540
nmのみの測定)。それぞれの結果を第4図及び第1表
、第2表に示した。
Measurement items (1)' (2) and (3) were measured using the above reagents (for measurement item (3), 540
measurement in nm only). The results are shown in FIG. 4 and Tables 1 and 2.

以下余白 第1表 各数値の単位 ■/dl ビリルビン量 5ITf/dI 第1表から、本発明によれば比較例(従来法)と比較し
てインジカンの影響が明らかに回避されていることがわ
かる。
Below is the margin in Table 1. Unit of each numerical value ■/dl Bilirubin amount 5ITf/dI From Table 1, it can be seen that according to the present invention, the influence of indican is clearly avoided compared to the comparative example (conventional method). .

以下余白 第2表 表中、W:波長(nm)、A:正品検体、B:人工透析
検体、各測定値の単位:■/dl、各試ネ−1の使用量
:Q、1mj!である。尚、エヘリンマロイ法は品性に
よって行ったが、この方法自体公知であるからその詳細
については説明を省略しである第2表から、正常検体で
は、いずれの方法においても殆ど測定値の差はあられれ
ないが、人工透析検体では比較例の方が著しい高値を示
すことがわかった。本発明では、従来のエベリンマロイ
法の場合と測定値がよく一致しており、比較例のような
従来の安定化ジアゾニウム塩法に比べて改善されている
ことがわかる。また、本発明において測定波長が540
nmよりも570 rimの方が誤差が少ないことが示
されているが、これは570nmにおいてインジカンの
色のかぶりが少ないためである。
In Table 2 in the margin below, W: Wavelength (nm), A: Genuine sample, B: Artificial dialysis sample, Unit of each measurement value: ■/dl, Amount used for each sample: Q, 1 mj! It is. The Eherin-Malloy method was performed based on quality, but since this method itself is well known, the details are omitted. From Table 2, it can be seen that for normal samples, there is almost no difference in the measured values with either method. However, it was found that the comparative example showed a significantly higher value in artificial dialysis samples. In the present invention, the measured values are in good agreement with those of the conventional Evelin Malloy method, and it can be seen that the present invention is improved compared to the conventional stabilized diazonium salt method as in the comparative example. In addition, in the present invention, the measurement wavelength is 540
It has been shown that there is less error at 570 rim than at 570 nm, which is due to less color cast in indican at 570 nm.

【図面の簡単な説明】[Brief explanation of drawings]

第1図〜第4図はそれぞれ実施例1〜3及び比較例の吸
収スペクトルを示す図面である。
FIGS. 1 to 4 are drawings showing absorption spectra of Examples 1 to 3 and Comparative Example, respectively.

Claims (5)

【特許請求の範囲】[Claims] (1)安定化ジアゾニウム塩を用いる総ビリルビンの測
定法において、反応促進剤としてグイフィリンを用い、
緩衝系に有機酸を用いることを特徴とする血液中の総ビ
リルビンの測定法。
(1) In the method for measuring total bilirubin using a stabilized diazonium salt, using guiphylline as a reaction accelerator,
A method for measuring total bilirubin in blood, characterized by using an organic acid in the buffer system.
(2)有機酸がクエン酸及びその塩類、コハク酸及びそ
の塩類、マレイン酸及びその塩類及び酒石酸及びその塩
類であることを特徴とする特許請求の範囲第1項記載の
方法。
(2) The method according to claim 1, wherein the organic acid is citric acid and its salts, succinic acid and its salts, maleic acid and its salts, and tartaric acid and its salts.
(3)グイフィリンを2〜10g/dl用いることを特
徴とする特許請求の範囲第1項又は第2項記載の方法。
(3) The method according to claim 1 or 2, characterized in that 2 to 10 g/dl of guiphylline is used.
(4)有機酸を5〜200mma r/l用いることを
特徴とする特許請求の範囲第1項〜第3項のいずれか1
項に記載の方法。
(4) Any one of claims 1 to 3, characterized in that 5 to 200 mmar/l of organic acid is used.
The method described in section.
(5)緩衝系のp Hが2〜4であることを特徴とする
特許請求の範囲第1項〜第4項のいずれが1項に記載の
方法。
(5) The method according to any one of claims 1 to 4, wherein the pH of the buffer system is 2 to 4.
JP21763782A 1982-12-11 1982-12-11 Measuring method of total bilirubin in blood Pending JPS59107264A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP21763782A JPS59107264A (en) 1982-12-11 1982-12-11 Measuring method of total bilirubin in blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21763782A JPS59107264A (en) 1982-12-11 1982-12-11 Measuring method of total bilirubin in blood

Publications (1)

Publication Number Publication Date
JPS59107264A true JPS59107264A (en) 1984-06-21

Family

ID=16707380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP21763782A Pending JPS59107264A (en) 1982-12-11 1982-12-11 Measuring method of total bilirubin in blood

Country Status (1)

Country Link
JP (1) JPS59107264A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158507A2 (en) * 1984-04-09 1985-10-16 EASTMAN KODAK COMPANY (a New Jersey corporation) Reagent composition, dry element and method for determination of total bilirubin
US4851383A (en) * 1987-06-08 1989-07-25 Ricoh Electronics, Inc. Non-laminate thermosensitive, pressure sensitive label and method of manufacture
US5508247A (en) * 1994-09-26 1996-04-16 Ricoh Electronics, Inc. Linerless direct thermal label
US5587214A (en) * 1994-05-13 1996-12-24 Media Solutions, Inc. Laminated thermal transfer printable labels
US5658661A (en) * 1995-08-29 1997-08-19 Media Solutions, Inc. Matted release coat for self-wound thermal printable facestock
US5661099A (en) * 1994-02-28 1997-08-26 Media Solutions, Inc. Self-wound direct thermal printed labels
JP2021514352A (en) * 2018-02-23 2021-06-10 バイオトロニック アクチェンゲゼルシャフト Parenteral pharmaceutical materials and methods for 40-O-cyclic hydrocarbon esters and related structures

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158507A2 (en) * 1984-04-09 1985-10-16 EASTMAN KODAK COMPANY (a New Jersey corporation) Reagent composition, dry element and method for determination of total bilirubin
US4851383A (en) * 1987-06-08 1989-07-25 Ricoh Electronics, Inc. Non-laminate thermosensitive, pressure sensitive label and method of manufacture
US5661099A (en) * 1994-02-28 1997-08-26 Media Solutions, Inc. Self-wound direct thermal printed labels
US5587214A (en) * 1994-05-13 1996-12-24 Media Solutions, Inc. Laminated thermal transfer printable labels
US5738748A (en) * 1994-05-13 1998-04-14 Media Solutions, Inc. Method of making laminated thermal transfer printable labels
US5508247A (en) * 1994-09-26 1996-04-16 Ricoh Electronics, Inc. Linerless direct thermal label
US5658661A (en) * 1995-08-29 1997-08-19 Media Solutions, Inc. Matted release coat for self-wound thermal printable facestock
JP2021514352A (en) * 2018-02-23 2021-06-10 バイオトロニック アクチェンゲゼルシャフト Parenteral pharmaceutical materials and methods for 40-O-cyclic hydrocarbon esters and related structures

Similar Documents

Publication Publication Date Title
Schade et al. Bound iron and unsaturated iron-binding capacity of serum; rapid and reliable quantitative determination
Lathe et al. Factors affecting the rate of coupling of bilirubin and conjugated bilirubin in the van den Bergh reaction
US5612223A (en) Cyanide-free reagent and method for the determination of hemoglobin
Boxer et al. Determination of thiocyanate in body fluids
CA1129322A (en) Determination of protein
Godman et al. The composition of the LE and hematoxylin bodies of systemic lupus erythematosus
JPS59107264A (en) Measuring method of total bilirubin in blood
EP0517914A1 (en) Reagent and methods for calcium determination.
Hood A–Z of clinical chemistry: a guide for the trainee
JP2004138408A (en) Specimen for measuring creatinine
US6066505A (en) Fluorescence polarization immunoassay
US4404286A (en) Bilirubin assay
US4119401A (en) Total bilirubin assay
Bardos et al. Spectrophotometric and chemical studies of 5‐mercaptouracil, 5‐mercaptodeoxyuridine, and their S‐substituted derivatives
CN109164259A (en) A kind of hoptoglobin detection kit of high sensitivity
WO1992011523A2 (en) Reagent and method for serum iron assay
Ginsberg et al. Sensitive methods for the determination of ester sulfate in biological systems
CA1089460A (en) Assay of iron and iron binding protein, reagents and methods
JP2632989B2 (en) Method for measuring unsaturated iron binding ability
JPH0154669B2 (en)
Sajiki et al. Method for determination of uric acid in viscera
Jaschonek et al. Platelet prostacyclin binding in smokers
US20020146630A1 (en) Non-oxidizable bilirubin substitutes and uses therefor
Pashley et al. Some drugs and other substances that interfere with protein determination
JPS6049256B2 (en) Shiyaku for protein analysis